跳至主要内容
临床试验/NCT04426422
NCT04426422已完成4 期

Effect of Metformin on Gut Microbiota Changes and Glycemic Control of Newly Diagnosed Type 2 Diabetes

Shenzhen People's Hospital1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2017年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
52
试验地点
1
主要终点
gut micribiota

研究概览

简要总结

This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients.

详细描述

This study was aimed to investigate the effect of metformin on the gut microbiota and glycemic control in newly diagnosed type 2 diabetes patients. All the recurited patients were treated with metformin 1500-2000mg daily for 3 months. Stool specimens and blood samples were collected at the beginning and 3 months later.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • newly diagnosis type 2 diabetes ,HbA1c >7 %

排除标准

  • history of cardiovascular disease, hypertension, severe renal dysfunction defined as glomerular filtration rate < 45 mL/min/1.73 m2; severe illness or diabetic ketoacidosis within 30 days, inability to tolerate ≥500 mg metformin twice per day and pregnancy.

研究组 & 干预措施

metformin group

Experimental

all the patients were treated with metformin 1500-2000mg daily for 3 months.

干预措施: Metformin Hydrochloride (Drug)

结局指标

主要结局

gut micribiota

时间窗: 3 months

the changes of gut micribiota

次要结局

  • glycemic control(3 months)

研究者

发起方
Shenzhen People's Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验